Exagen is engaged in commercializing a portfolio of testing products under its AVISE® brand, several of which are based on its Cell-Bound Complement Activation Products (CB-CAPs) technology. CB-CAPs assess the activation of the complement system, a biological pathway that is implicated across various autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE). Co.'s main testing product, AVISE® CTD, enables diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs), and other related diseases with overlapping symptoms. AVISE® CTD utilizes Co.'s CB-CAPs technology to enable the diagnosis SLE. The XGN stock yearly return is shown above.
The yearly return on the XGN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the XGN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|